TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7498565

Group type: EXPERIMENTAL
Intervention: Pilocarpine 4% drops
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of Pilocarpine 4% and Phenylephrine 10% drops
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (Phenylephrine 10% drops alone)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Phenylephrine 10% drops
Number of subjects: 17
Study: 1685945

Group type: EXPERIMENTAL
Intervention: loratadine (10 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: beclomethasone dipropionate (100 micrograms in each nostril twice daily)
Number of subjects: 60
Study: 7390386

Group type: EXPERIMENTAL
Intervention: Lipo-Merz retard (1 capsule/day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Commercial combination product (1 capsule three times daily)
Number of subjects: 98
Study: 30521757

Group type: EXPERIMENTAL
Intervention: Solriamfetol 37.5 mg
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Solriamfetol 75 mg
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Number of subjects: 476

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Solriamfetol (all doses except 37.5 mg)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 476
Study: 27427786

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at a dosage of 90 μg/kg, administered in one to three doses for joint bleeding treatment.
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Self-administered additional haemostatic medication (AHM) up to 48 hours after the first rFVIIa treatment.
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Time to treatment initiation.
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Pain and pain VAS assessments.
Number of subjects: 177
Study: 25282123

Group type: EXPERIMENTAL
Intervention: AHA Heartsaver CPR class augmented with a musical metronome (tempo of 100 beats/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AHA Heartsaver CPR class (standard CPR educational experience)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AHA Heartsaver CPR class augmented with a musical metronome
Number of subjects: 0
Study: 23370083

Group type: EXPERIMENTAL
Intervention: Expressive suppression
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 224
Study: 21597261

Group type: EXPERIMENTAL
Intervention: Terazosin 2 mg (once nightly) for 4 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 73
Study: 18626523

Group type: EXPERIMENTAL
Intervention: Venous occlusion with lidocaine for 15 seconds (group I, n=50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Venous occlusion with lidocaine for 30 seconds (group II, n=50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Venous occlusion with lidocaine for 60 seconds (group III, n=50)
Number of subjects: 150
Study: 16282583

Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bone-hamstring-bone
Number of subjects: 80
Study: 12510249

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramipril (ACE inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan (Angiotensin-receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study: 10727543

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1650
Study: 1401438

Group type: EXPERIMENTAL
Intervention: Fluoride gel (FG; 1.1% NaF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride rinse (FR; 0.05% NaF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (FD; 0.24% NaF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo dentifrice (PD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Night-time fluoride application
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stimulated parotid saliva sampling
Number of subjects: 10
Study: 3998975

Group type: EXPERIMENTAL
Intervention: 1% silver nitrate prophylaxis
Number of subjects: 145

Group type: COMPARATOR
Intervention: 1% tetracycline prophylaxis
Number of subjects: 145
Study: 31256094

Group type: EXPERIMENTAL
Intervention: Versatile physiotherapy intervention conducted in accordance with European Physiotherapy Guideline for Parkinson's Disease (EPGPD), 16 one-hour therapy sessions (twice per week) over 10 weeks.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Versatile physiotherapy intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study: 29739374

Group type: EXPERIMENTAL
Intervention: Baby Friendly Community Initiative (BFCI)
Number of subjects: 270
Study: 26517202

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441mg
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882mg
Number of subjects: 622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (both doses)
Number of subjects: 622
Study: 24894359

Group type: EXPERIMENTAL
Intervention: Classroom experiences with more instructional/emotional support
Number of subjects: 136
Study: 22409596

Group type: EXPERIMENTAL
Intervention: USG‐PIVA (Ultrasound-guided peripheral venous access)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blind technique (B)
Number of subjects: 20
Study: 20219294

Group type: EXPERIMENTAL
Intervention: woman-focused intervention
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: modified NIDA intervention
Number of subjects: 455

Group type: COMPARATOR
Intervention: delayed-treatment control condition
Number of subjects: 455
Study: 19030203

Group type: EXPERIMENTAL
Intervention: Pantoprazole (PPI) treatment
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Primary care treatment (not according to study protocol)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 114
Study: 16037177

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine (300 microg in 2 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine (10 mg)
Number of subjects: 60
Study: 12067088

Group type: EXPERIMENTAL
Intervention: CM acupuncture (real treatment)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham acupuncture (control treatment)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both treatments (real and sham)
Number of subjects: 29
Study: 10066998

Group type: EXPERIMENTAL
Intervention: AX version of the Continuous Performance Test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stroop task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lexical disambiguation task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Depressed controls
Number of subjects: 0
Study: 8879853

Group type: EXPERIMENTAL
Intervention: Single large i.v. dose of gentamicin (10 mg/kg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard multiple dose regimen of gentamicin (2.5 mg/kg i.v. stat and then divided doses)
Number of subjects: 53
Study: 1638335

Group type: EXPERIMENTAL
Intervention: 200 mg disulfiram
Number of subjects: 126

Group type: COMPARATOR
Intervention: 100 mg vitamin C
Number of subjects: 126
Study: 6542082

Group type: EXPERIMENTAL
Intervention: Methylphenidate (dosage titrated based on augmenter-reducer classification and pretreatment HR levels)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31113542

Group type: EXPERIMENTAL
Intervention: Reduction of NICU light and noise levels during skin-to-skin care (SSC)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nine selected interventions to reduce light and noise levels
Number of subjects: 21
Study: 29769026

Group type: EXPERIMENTAL
Intervention: CareWell program (multidisciplinary team meetings, proactive care planning, case management, medication reviews)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: CareWell program
Number of subjects: 204
Study: 27349717

Group type: EXPERIMENTAL
Intervention: Combination oral care (tooth brushing, chlorhexidine, and cold water)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (standard oral care regimen)
Number of subjects: 39
Study: 24662027

Group type: EXPERIMENTAL
Intervention: Pegylated feline granulocyte colony-stimulating factor (PegFeG-CSF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Feline granulocyte colony-stimulating factor (FeG-CSF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Human granulocyte colony-stimulating factor (HuG-CSF)
Number of subjects: 37
Study: 22042323

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19913895

Group type: EXPERIMENTAL
Intervention: High CA-IX expression
Number of subjects: 166
Study: 17874122

Group type: EXPERIMENTAL
Intervention: Extra load on shoulders (10% of body mass)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Extra load around waists (10% of body mass)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal (baseline) condition
Number of subjects: 24
Study: 16225571

Group type: EXPERIMENTAL
Intervention: Kiwi Omnicup
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard vacuum cup (silastic or metal)
Number of subjects: 194
Study: 12399701

Group type: EXPERIMENTAL
Intervention: Bibliotherapy (cognitive-behavioural self-help booklet for health anxiety sufferers)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No bibliotherapy (control group)
Number of subjects: 40
Study: 10827812

Group type: EXPERIMENTAL
Intervention: Rifaximin suspension 1800 mg three times a day plus Omeprazole 20 mg twice a day (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rifaximin pills 1800 mg three times a day plus Omeprazole twice a day (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rifaximin suspension
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rifaximin pills
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study: 8527469

Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE) assessment in Munich sample
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE) assessment in ECA sample
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Prevalence of major depression in Munich
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Prevalence of major depression in ECA study
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Prevalence of dysthymia in Munich
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Prevalence of dysthymia in ECA study
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Cognitive impairment in institutionalized individuals
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Cognitive impairment in females and oldest age cohort in ECA sample
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Major depression in institutionalized individuals in Munich
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Major depression in oldest age cohort in ECA study
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Association of dysthymia with sociodemographic factors
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Excess comorbidity of cognitive impairment and depression
Number of subjects: 1229
Study: 1810681

Group type: EXPERIMENTAL
Intervention: Atenolol, a beta 1‐selective adrenergic blocker, administered for an unspecified duration.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambulatory electrocardiographic monitoring to measure ischemic episodes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic impact of the diagnostic and therapeutic strategy.
Number of subjects: 0
Study: 7113629

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fentanyl 6 micrograms/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study: 31619115

Group type: EXPERIMENTAL
Intervention: Speech reception thresholds in spatially separated conditions (target at 0°, background noise at 90°)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Speech reception thresholds in collocated conditions (target and background at 0°)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Auditory stream segregation abilities in collocated conditions
Number of subjects: 39
Study: 28922268

Group type: EXPERIMENTAL
Intervention: In-bed cycling in addition to usual care physiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care physiotherapy alone (control)
Number of subjects: 30
Study: 26383783

Group type: EXPERIMENTAL
Intervention: TV Commercial Stepping
Number of subjects: 58

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 58
Study: 24222260

Group type: EXPERIMENTAL
Intervention: Clonidine (200-μg initially, then 100-μg due to side effects)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 23027480

Group type: EXPERIMENTAL
Intervention: Cementless hemiarthroplasties (Group 1)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cemented hemiarthroplasties (Group 2)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cementless and cemented hemiarthroplasties
Number of subjects: 94
Study: 19668780

Group type: EXPERIMENTAL
Intervention: Prehospital random assignment (n=145)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Arrival by ambulance without prehospital random assignment (n=90)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Ambulatory patients (n=93)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Community hospital (n=165)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: PCI hospital (n=163)
Number of subjects: 328
Study: 19161059

Group type: EXPERIMENTAL
Intervention: Intensive individual tooth brushing training every three months and guidance on oral health.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tooth brushing training once a year (Control).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Educational program (experimental group).
Number of subjects: 60
Study: 16080073

Group type: EXPERIMENTAL
Intervention: Tigecycline (initial dose of 100 mg, followed by 50 mg intravenously every 12 h)
Number of subjects: 1642

Group type: COMPARATOR
Intervention: Imipenem-cilastatin (500/500 mg intravenously every 6 h)
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 1642

Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 1642
Study: 11985298

Group type: EXPERIMENTAL
Intervention: Supportive interviewer
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nonsupportive interviewer
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Resistance Efficacy (mediator for older children)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Preexisting social support reserves
Number of subjects: 81
Study: 9498728

Group type: EXPERIMENTAL
Intervention: 50 mg Naltrexone (NTX)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 26
Study: 9098273

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost applied in the evening
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost applied in the morning
Number of subjects: 267

Group type: COMPARATOR
Intervention: 0.5% timolol applied twice daily
Number of subjects: 267
Study: 2230060

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 375342

Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose)
Number of subjects: 0
Study: 31856945

Group type: EXPERIMENTAL
Intervention: 4-session smoking cessation treatment
Number of subjects: 529
Study: 31508729

Group type: EXPERIMENTAL
Intervention: HyFlex CM (Coltene‐Whaledent, Altstetten, Switzerland)
Number of subjects: 24

Group type: COMPARATOR
Intervention: ProTaper Next (Dentsply Sirona, Ballaigues, Switzerland)
Number of subjects: 24
Study: 27779500

Group type: EXPERIMENTAL
Intervention: E‐go device training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional physiotherapy programs
Number of subjects: 19
Study: 25607226

Group type: EXPERIMENTAL
Intervention: Intravenous caffeine citrate (20 mg/kg) before 2 hours of age
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo at 12 hours of age
Number of subjects: 21
Study: 23433492

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation plus usual care (SCS group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care alone (UC group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Both groups (SCS and UC)
Number of subjects: 45
Study: 22002968

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 70

Group type: COMPARATOR
Intervention: 4% gelatin
Number of subjects: 70
Study: 19527897

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Systemic methotrexate (MTX)
Number of subjects: 72
Study: 17325606

Group type: EXPERIMENTAL
Intervention: 60-minute HIV and alcohol risk reduction behavioral skills intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: 20-minute HIV education condition (Control)
Number of subjects: 143
Study: 14702024

Group type: EXPERIMENTAL
Intervention: Independent evaluators' guesses about treatment condition during post-treatment assessments
Number of subjects: 170
Study: 11455377

Group type: EXPERIMENTAL
Intervention: Modified composite
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional glass ionomer
Number of subjects: 98
Study: 9741864

Group type: EXPERIMENTAL
Intervention: Immunization with paternal leukocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study: 8050210

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) erythropoietin (EPO) at a dose of 120 iu/kg/week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous (IV) erythropoietin (EPO) at a dose of 120 iu/kg/week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) EPO
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous (IV) EPO
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EPO withdrawal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) EPO and Intravenous (IV) EPO
Number of subjects: 16
Study: 3391624

Group type: EXPERIMENTAL
Intervention: Oxytetracycline and pyridostigmine in combination
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oxytetracycline alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pyridostigmine alone
Number of subjects: 12
Study: 31009861

Group type: EXPERIMENTAL
Intervention: Teach Two (simple structured direction)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Social (unstructured direction)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Teach Many (complex structured direction)
Number of subjects: 42
Study: 28215611

Group type: EXPERIMENTAL
Intervention: Prolotherapy injection (n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Exercise (control group; n=60)
Number of subjects: 120
Study: 25579292

Group type: EXPERIMENTAL
Intervention: 100 µg phenylephrine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 125 µg phenylephrine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 150 µg phenylephrine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Additional doses of phenylephrine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Number of additional boluses
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Number of hypotensive episodes
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Reactive hypertension or bradycardia
Number of subjects: 120
Study: 22571806

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Response Questionnaire
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Chalder Fatigue Scale
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Work and Social Adjustment Scale
Number of subjects: 640
Study: 21719110

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1g BID
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 18306478

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 122
Study: 16957412

Group type: EXPERIMENTAL
Intervention: 458 kcal diet for 1 month (Group A)
Number of subjects: 67

Group type: COMPARATOR
Intervention: 800 kcal diet for 3 months (Group B)
Number of subjects: 67
Study: 12851016

Group type: EXPERIMENTAL
Intervention: SF‐36 Health Survey
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 252
Study: 11099086

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin suspension (10 mg/kg twice a day + im placebo; n = 95)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Intramuscular ceftriaxone (50 mg/kg/day + placebo suspension; n = 106)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin suspension
Number of subjects: 201

Group type: COMPARATOR
Intervention: Intramuscular ceftriaxone
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 201

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 201
Study: 9124977

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg and Amiloride 5 mg orally added to furosemide treatment
Number of subjects: 210

Group type: COMPARATOR
Intervention: Furosemide (large doses > or = 80 mg/24 h)
Number of subjects: 210
Study: 8197425

Group type: EXPERIMENTAL
Intervention: Less than lobar resections
Number of subjects: 170